© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
A discussion on the management of cold agglutinin disease, and the impact of emerging therapies in the pipeline on payer and clinician considerations.
September 24th 2021
Jeremy Lorber, MD, explains what is known about the pathophysiology of a rare autoimmune hemolytic anemia, cold agglutinin disease.
Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias.
October 1st 2021
Health care professionals who treat patients with cold agglutinin disease, a rare autoimmune hemolytic anemia, comment on symptoms that make the condition difficult to diagnose and remark on the burden on patients.
Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.
October 8th 2021
Diagnostic criteria used by health care professionals who manage patients with autoimmune hemolytic anemias to help distinguish cold agglutinin disease from other medical conditions.
Clinicians offer their perspectives on establishing treatment goals for patients with cold agglutinin disease and describe how they measure treatment response.
October 15th 2021
Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.
A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.
October 22nd 2021
An overview of the roles of plasmapheresis, IVIG, transfusions, and corticosteroids as treatment for patients with cold agglutinin disease.
Special considerations educating health care professionals and patients about lifestyle interventions and cold avoidance for cold agglutinin disease.